Zealand Pharma A/S (ZLDPF)
35.50
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Zealand Pharma Enterprise Value : 407.51M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 407.51M |
| November 12, 2026 | 407.51M |
| November 11, 2026 | 491.55M |
| November 10, 2026 | 491.55M |
| November 09, 2026 | 498.27M |
| November 06, 2026 | 346.78M |
| November 05, 2026 | 399.45M |
| November 04, 2026 | 348.86M |
| November 03, 2026 | 348.86M |
| November 02, 2026 | 345.20M |
| October 30, 2026 | 244.83M |
| October 29, 2026 | 244.83M |
| October 28, 2026 | 244.83M |
| October 27, 2026 | 244.83M |
| October 26, 2026 | 244.83M |
| October 23, 2026 | 298.61M |
| October 22, 2026 | 340.29M |
| October 21, 2026 | 340.29M |
| October 20, 2026 | 305.33M |
| October 19, 2026 | 265.67M |
| October 16, 2026 | 306.67M |
| October 15, 2026 | 306.67M |
| October 14, 2026 | 317.43M |
| October 13, 2026 | 364.83M |
| October 12, 2026 | 364.83M |
| Date | Value |
|---|---|
| October 09, 2026 | 417.26M |
| October 08, 2026 | 544.66M |
| October 07, 2026 | 544.66M |
| October 06, 2026 | 583.65M |
| October 05, 2026 | 710.04M |
| October 02, 2026 | 710.04M |
| October 01, 2026 | 582.31M |
| September 30, 2026 | 956.09M |
| September 29, 2026 | 783.16M |
| September 28, 2026 | 783.16M |
| September 25, 2026 | 783.16M |
| September 24, 2026 | 783.16M |
| September 23, 2026 | 861.00M |
| September 22, 2026 | 861.00M |
| September 21, 2026 | 853.67M |
| September 18, 2026 | 853.67M |
| September 17, 2026 | 853.67M |
| September 16, 2026 | 853.67M |
| September 15, 2026 | 853.67M |
| September 14, 2026 | 853.67M |
| September 11, 2026 | 1.089B |
| September 10, 2026 | 1.089B |
| September 09, 2026 | 1.089B |
| September 08, 2026 | 1.089B |
| September 04, 2026 | 1.178B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Genmab A/S | 34.93B |
| Ascendis Pharma A/S | 17.48B |
| Bavarian Nordic A/S | 2.199B |
| Evaxion AS | 15.96M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.311M |
| Revenue (Quarterly) | 0.6156M |
| Total Expenses (Quarterly) | 8.927M |
| EPS Diluted (Quarterly) | -0.1216 |
| Gross Profit Margin (Quarterly) | -200.0% |
| Profit Margin (Quarterly) | -1.35K% |
| Earnings Yield | 19.09% |
| Operating Earnings Yield | 13.30% |
| Normalized Earnings Yield | 16.57 |